Effects of multidose simvastatin co-administration on pharmacokinetic profile of apatinib in rats by UPLC-MS/MS.
Effects of multidose simvastatin co-administration on pharmacokinetic profile of apatinib in rats by UPLC-MS/MS.
Xenobiotica. 2020 Mar 09;:1-21
Authors: Gao J, Ren H, Feng Z, Chen S, Liang Y, Liu W, Zhou Q, Wang M
Abstract
Apatinib, a small molecule anti-angiogenic tyrosine kinase inhibitor (TKI), is used extensively to treat advanced gastric cancer and simvastatin (SV) is often co-prescribed to treat cardiovascular disease in cancer patients. As both apatinib and SV are metabolized primarily by CYP3A4, they are likely to interact. Therefore, the potential effect of SV co-administration on pharmacokinetics of apatinib in Sprague-Dawley male rats is demonstrated for the first time.Sixteen rats were randomly divided into two groups (nâ=â8), group B (2âmg/kg SV orally co-administrated for 7 days) and the corresponding control group (group A). Apatinib concentrations of rat plasma samples were detected by UPLC-MS/MS. Pharmacokinetic parameters were calculated using non compartmental methods.Co-administration of SV for 7 days significantly increased AUC(0-t), AUC(0-â) and Cmax of apatinib by 2.4-fold, 2.4-fold and 2.7-fold, while decreasing Vz/F and CLz/F by 81.7% and 73.9%.These findings suggest that concomitant administration of SV with 7 days may have inhibited the metabolism of apatinib in rats.
PMID: 32150479 [PubMed - as supplied by publisher]
Source: Xenobiotica - Category: Research Authors: Gao J, Ren H, Feng Z, Chen S, Liang Y, Liu W, Zhou Q, Wang M Tags: Xenobiotica Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Gastric (Stomach) Cancer | Gastroenterology | Heart | Research | Simvastatin | Statin Therapy | Zocor